Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.
IBO stock price ended at $0.46 on 星期二, after rising 2.22%
On the latest trading day Jan 20, 2026, the stock price of IBO rose by 2.22%, climbing from $0.47 to $0.46. Throughout the session, the stock experienced a volatility of 4.44%, with prices fluctuating between a daily low of $0.45 and a high of $0.47. Alongside this price increase, trading volume also rose by 4.6K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 35.2K shares were traded, amounting to a market value of approximately $48.1M.